Skip to main content

Bienaime Jean Jacques's Form 4 filing

Biomarin Pharmaceutical Inc (BMRN) · filed May 13, 2024

Accession no.
0001048477-24-000079
Filed
May 13, 2024
Trade date
May 9-10, 2024
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $3.26M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bienaime Jean JacquesCIK 0001221590Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 9, 2024Common StockMOption exerciseAcquired+20,000$63.10+$1,262,000494,994Direct
May 9, 2024Common StockSSaleDisposed−20,000$81.62−$1,632,400474,994Direct
May 10, 2024Common StockMOption exerciseAcquired+20,000$63.10+$1,262,000494,994Direct
May 10, 2024Common StockSSaleDisposed−20,000$81.14−$1,622,800474,994Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 9, 2024Common StockMOption exerciseDisposed−20,000$0.00$071,000Direct
May 10, 2024Common StockMOption exerciseDisposed−20,000$0.00$051,000Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)